Pet medication developer Aratana Therapeutics sets terms for $51 million IPO

By
A A A

Aratana Therapeutics, which is focused on the development and commercialization of prescription medication for pets, announced terms for its IPO on Thursday. The Kansas City, KS-based company plans to raise $51 million by offering 4.3 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Aratana Therapeutics would command a market value of $223 million. The company filed for an IPO with a proposed deal size of $58 million in March. 

Aratana Therapeutics, which was founded in 2010 and has yet to generate any revenue, plans to list on the NASDAQ under the symbol PETX. Stifel and Lazard Capital Markets are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: PETX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com